var data={"title":"Benznidazole (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Benznidazole (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/815017?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50553478\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiprotozoal, Nitroimidazole;</li>\n      <li>\n        Antitrypanosomal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625938\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chagas disease (off-label use):</b> Oral: 5 to 7 mg/kg/day in 2 divided doses for 60 days (Bern 2007; CDC 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991557\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988800\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625965\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chagas disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children 2 to 12 years of age:</i> Oral: 5 to 8 mg/kg/day in 2 divided doses for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adolescents (off-label use):</i> Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51090208\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51090209\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625967\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50768236\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12.5 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50768235\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50553477\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Benznidazole tablets: FDA approved August 2017; anticipated availability is currently undetermined. However, product may be obtained from the CDC via the existing IND protocol. Additional information from the CDC is available at <a target=\"_blank\" href=\"https://www.cdc.gov/laboratory/drugservice/formulary.html&amp;token=8fUMx+fB4trlY8x/Mo8Y9Ddj5kItZ1H7qlW/e3GJptY28xGubTU0DXWzUi5nl8+CwNhzfAcY95p7Mq5fGdd6Fg==&amp;TOPIC_ID=114673\" target=\"_blank\">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625658\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Benznidazole will be commercially available in the United States labeled for pediatric patients 2 to 12 years of age; however, anticipated availability is currently undetermined. It is currently available for the treatment of Chagas disease (American trypanosomiasis) through the CDC Drug Service for patients of all ages that meet the eligibility criteria in the Investigational New Drug (IND) protocol. Contact the CDC Drug Service at 404-639-3670 or drugservice@cdc.gov. Additional information from the CDC is available at <a target=\"_blank\" href=\"https://www.cdc.gov/laboratory/drugservice/formulary.html&amp;token=8fUMx+fB4trlY8x/Mo8Y9Ddj5kItZ1H7qlW/e3GJptY28xGubTU0DXWzUi5nl8+CwNhzfAcY95p7Mq5fGdd6Fg==&amp;TOPIC_ID=114673\" target=\"_blank\">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625978\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer with or without food, approximately 12 hours apart.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">To make slurry using 12.5 or 100 mg tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Place prescribed dose in a cup and add the specified volume of water (also refer to manufacturer's labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12.5 mg tablets: 40 mL for 4 tablets, 50 mL for 5 tablets, or 60 mL for 6 tablets</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">100 mg tablets: 80 mL for 1 tablet, 120 mL for 1.5 tablets, or 160 mL for 2 tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow tablets to disintegrate over 1 to 2 minutes. Shake cup gently to mix and administer contents immediately. Rinse cup with an additional 10 mL (for 12.5 mg tablets) or 80 mL (for 100 mg tablets) of water and administer entire amount.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625926\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Benznidazole may cause carcinogenicity, teratogenicity (or other developmental toxicity), reproductive toxicity, and/or genotoxicity. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, if unable to swallow whole), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50553480\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chagas disease:</b> Treatment of Chagas disease (American trypanosomiasis) caused by <i>Trypanosoma cruzi </i>in pediatric patients 2 to 12 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50586842\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (16%), skin lesion (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (25%), decreased appetite (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (7%), peripheral neuropathy (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5%), vomiting (5%), anorexia (&lt;5%), diarrhea (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&lt;5%), tremor (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute generalized exanthematous pustulosis, ageusia, agranulocytosis, amnesia, arthritis, disorientation, dress syndrome, edema, epigastric pain, erythema multiforme, erythematous plaques, erythematous rash, exfoliation of skin, exfoliative dermatitis, eyelid edema, fatigue, fever, granulocytopenia, headache, hepatitis, hypoesthesia, increased serum alkaline phosphatase, increased serum bilirubin, insomnia, lack of concentration, lymphadenopathy, maculopapular rash, musculoskeletal pain, myalgia, paresthesia, pruritic rash, seizure, skin blister, swelling of extremities, thrombocytopenia, toxic epidermal necrolysis, toxic hepatitis, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50553481\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to benznidazole, other nitroimidazole derivatives, or any component of the formulation; disulfiram within previous 2 weeks of benznidazole therapy; consumption of alcoholic beverages or products containing propylene glycol during and for at least 3 days after therapy with benznidazole</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625922\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic/genotoxic: Carcinogenicity has been observed in mice and rats with nitroimidazole agents that are structurally similar to benznidazole in animal studies; it is unknown whether benznidazole is associated with carcinogenicity in humans. Genotoxicity (two-fold increase in chromosomal aberrations) of benznidazole has been demonstrated in one study of pediatric patients (11 months to 11 years) with Chagas disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Paresthesia and/or peripheral neuropathy have been reported and may take several months to resolve; in general, these symptoms occur late in the course of treatment. Headache and dizziness have also been reported. Discontinue treatment if neurologic signs or symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Serious skin and subcutaneous disorders (eg, acute generalized exanthematous pustulosis, toxic epidermal necrolysis, erythema multiforme, eosinophilic drug reaction) have been reported. Extensive skin reactions (eg, rash [maculopapular, pruritic macules, eczema, pustules, erythematous, generalized], allergic dermatitis, exfoliative dermatitis) have also been reported, most cases occurring after ~10 days of treatment; most rashes resolved with treatment discontinuation. Discontinue treatment at first evidence of a serious cutaneous reaction or skin reactions presenting with systemic signs/symptoms (eg, lymphadenopathy, fever, purpura).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Bone marrow depression (eg, neutropenia, thrombocytopenia, anemia, leukopenia) that resolved after treatment discontinuation has been reported. Use benznidazole with caution and under strict medical supervision in patients with hematological manifestations of bone marrow depression. Monitor CBC, as well as total and differential leukocyte counts, prior to initiation, during treatment, and after discontinuation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Abdominal cramps, nausea, vomiting, headaches, and flushing have been reported with nitroimidazole agents that are structurally related to benznidazole and concomitant alcohol consumption (disulfiram-like reactions); avoid alcoholic beverages or products containing propylene glycol during and for at least 3 days after therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50615994\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50615991\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114673&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Benznidazole may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: Benznidazole may enhance the adverse/toxic effect of Disulfiram. In particular, the risk for CNS toxicities such as psychosis may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Products Containing Propylene Glycol: Benznidazole may enhance the adverse/toxic effect of Products Containing Propylene Glycol. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625665\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Information related to the use of benznidazole for the treatment of acute Chagas disease in pregnant women is limited; treatment of chronic disease during pregnancy is not recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Congenital transmission of Chagas disease may occur and the actual risk may depend on stage of maternal disease and geographic location (Bittencourt 1992). There are no specific recommendations for preventing vertical transmission of disease in women who are already pregnant. Because treatment is associated with a high risk of adverse events in adults and there is lack of data on possible teratogenic effects, treatment during pregnancy is not currently recommended (Carlier 2011). However, therapy with benznidazole prior to pregnancy in women who test positive for <i>Trypanosoma cruzi</i> antibodies may be used to prevent congenital transmission (Alvarez 2017; Carlier 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females of reproductive potential should have a pregnancy test prior to therapy. Effective contraception should be used during treatment and for 5 days after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625918\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of benznidazole is 17% when calculated using the highest breast milk concentration located and compared with a weight-adjusted maternal dose of 5.2 mg/kg/day (300 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The RID of benznidazole was calculated by the authors of a study using a milk concentration of 5.9 mg/L, providing an estimated daily infant dose via breast milk of 0.89 mg/kg/day. This milk concentration was obtained following maternal administration of oral benznidazole 5.2 mg/kg/day (300 mg/day). The sample was obtained 2 hours after the maternal dose, 7 days after treatment started. The study included a total of 12 women, 10 who provided breast milk samples. Breast milk concentrations correlated with maternal serum concentration. The RID of benznidazole ranged from 5.5% to 17% (median 12.3%). Three women withdrew from the study due to adverse events. Adverse events were not observed in any infant (Garc&iacute;a-Bournissen 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disease transmission may occur in women with bleeding nipples (Bittencourt 1992). Maternal treatment for Chagas disease should be considered after breastfeeding has stopped (Carlier 2011). Due to the potential transmission of Chagas disease as well as the potential for serious adverse events in the breastfeeding infant, breastfeeding during benznidazole therapy is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625980\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC and total and differential leukocyte counts prior to initiation, during treatment, and after discontinuation; pregnancy test prior to initiation in female patients; signs of skin rash or neurologic signs/symptoms during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625930\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits the synthesis of DNA, RNA, and proteins within the <i>T. cruzi</i> parasite.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50625931\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid (Bern 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~44% to 60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Unknown</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Median: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine and feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50771511\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Benznidazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $300.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $360.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50615788\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abarax (AR);</li>\n      <li>Radanil (AR);</li>\n      <li>Ragonil (EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &Aacute;lvarez MG, Vigliano C, Lococo B, Bertocchi G, Viotti R. Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study. <i>Acta Trop</i>. 2017;174:149-152. doi: 10.1016/j.actatropica.2017.07.004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/28720492/pubmed\" target=\"_blank\" id=\"28720492\">28720492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi: 10.1002/cpt.377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benznidazole [prescribing information]. Florham Park, NJ: Exeltis USA Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. <i>JAMA</i>. 2007;298(18):2171-2181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/18000201/pubmed\" target=\"_blank\" id=\"18000201\">18000201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bittencourt AL. Possible risk factors for vertical transmission of Chagas' disease. <i>Rev Inst Med Trop Sao Paulo</i>. 1992;34(5):403-408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/1342103/pubmed\" target=\"_blank\" id=\"1342103\">1342103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22039554\"></a>Carlier Y, Torrico F, Sosa-Estani S, et al. Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. <i>PLoS Negl Trop Dis</i>. 2011;5(10):e1250. doi: 10.1371/journal.pntd.0001250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/22039554/pubmed\" target=\"_blank\" id=\"22039554\">22039554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Parasites-American Trypanosomiasis (also known as Chagas Disease). <a href=\"https://www.cdc.gov/parasites/chagas/health_professionals/tx.html\" target=\"_blank\">https://www.cdc.gov/parasites/chagas/health_professionals/tx.html</a>. Published August 10, 2017. Updated August 31, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25210104\"></a>Garc&iacute;a-Bournissen F, Moroni S, Marson ME, et al. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. <i>Arch Dis Child</i>. 2015;100(1):90-94. doi: 10.1136/archdischild-2014-306358.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/25210104/pubmed\" target=\"_blank\" id=\"25210104\">25210104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed September 20, 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114673 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50553478\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50625938\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991557\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988800\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50625965\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51090208\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51090209\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50625967\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50768236\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50768235\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50553477\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F50625658\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50625978\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F50625926\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50553480\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50586842\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50553481\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50625922\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50615994\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50615991\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50625665\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50625918\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50625980\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50625930\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50625931\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50771511\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50615788\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/114673|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}